scholarly journals Early Prediction of Tumor Response: A Future Strategy for Optimizing Cancer Treatment

10.5772/57120 ◽  
2013 ◽  
Author(s):  
Shigeto Ueda ◽  
Toshiaki Saeki
Keyword(s):  
Cancer Treatment ◽  
Tumor Response ◽  
Early Prediction ◽  
Future Strategy

scholarly journals Early Prediction of Histopathological Tumor Response to Preoperative Chemotherapy by Tc-99m MIBI Imaging in Bone and Soft Tissue Sarcomas

2010 ◽  
Vol 35 (3) ◽  
pp. 154-159 ◽  
Author(s):  
Junichi Taki ◽  
Anri Inaki ◽  
Hiroshi Wakabayashi ◽  
Hisashi Sumiya ◽  
Hiroyuki Tsuchiya ◽  
...  
Keyword(s):  
Soft Tissue ◽  
Preoperative Chemotherapy ◽  
Tumor Response ◽  
Soft Tissue Sarcomas ◽  
Early Prediction

scholarly journals The Functional Diffusion Map: An Imaging Biomarker for the Early Prediction of Cancer Treatment Outcome

Neoplasia ◽  
2006 ◽  
Vol 8 (4) ◽  
pp. 259-267 ◽  
Author(s):  
Bradford A. Moffat ◽  
Thomas L. Chenevert ◽  
Charles R. Meyer ◽  
Paul E. Mckeever ◽  
Daniel E. Hall ◽  
...  
Keyword(s):  
Treatment Outcome ◽  
Cancer Treatment ◽  
Imaging Biomarker ◽  
Early Prediction ◽  
Diffusion Map

A prospective observational clinical study involving an alternative cancer treatment, psorinum therapy, in treating stomach, gallbladder, pancreas, and liver cancers

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. 3050-3050 ◽  
Author(s):  
A. Chatterjee ◽  
S. Bhattacharya ◽  
A. K. Chatterjee ◽  
J. Biswas ◽  
B. Mukhopadhyay
Keyword(s):  
Clinical Study ◽  
Side Effects ◽  
Cancer Treatment ◽  
Late Stage ◽  
Tumor Response ◽  
Stage Ii ◽  
Stage Iii ◽  
Secondary Outcome ◽  
Secondary Outcome Measure ◽  
Liver Cancers

3050 Background: The prospective observational clinical study was conducted to know the efficacy of an alternative cancer treatment, ‘psorinum therapy,‘ in treating liver, gall bladder, pancreatic, and stomach cancers. The primary outcome measures of the study were (1) to assess the radiological tumor response; (2) to assess how many participants survived at least 1 year, 2 years, 3 years, 4 years, and finally, 5 years after the beginning of the study. The secondary outcome measure of the study was to assess the side effects of the investigational anti-cancer drug (psorinum) if any. Methods: The drug psorinum (an alcoholic extract of scabies, scrub, slough, and pus cells) was administered orally at 0.01ml-0.02 ml/Kg body weight as a single dose in empty stomach per day and ongoing to all the participants along with allopathic and homeopathic supportive cares. Results: 158 histopathology or cytopathology proved participants (42 of stomach, 40 of gallbladder, 44 of pancreas, and 32 of liver cancers) were included in the final analysis at the end of the study. According to the AJCC/UICC TNM staging system, 7 (4.43%) of them diagnosed at stage II, 39 (24.68%) of them diagnosed at late stage II or early stage III and 112 (70.87%) of them diagnosed at late stage III or stage IV. According to the RECIST criteria, complete tumor response occurred in 28 (17.72%) cases and partial tumor response occurred in 56 (35.44%) cases. 126 (79.75%) of them survived at least 1 year, 99 (62.66%) of them survived at least 2 years, 87 (55.06%) of them survived at least 3 years, 76 (48.10%) of them survived at least 4 years, and 62 (39.24%) of them survived at least 5 years. These participants did not receive any other conventional or investigational cancer treatments. The participants report no side effects from the drug psorinum. Conclusions: Psorinum therapy is effective in treating stomach, gallbladder, pancreas, and liver cancers. Double-blinded randomized controlled clinical trial should be done for further investigation of this alternative cancer treatment. No significant financial relationships to disclose.

Characterization of cervical lymph-nodes using a multi-parametric and multi-modal approach for an early prediction of tumor response to chemo-radiotherapy

2016 ◽  
Vol 32 (12) ◽  
pp. 1672-1680 ◽  
Author(s):  
Elisa Scalco ◽  
Simona Marzi ◽  
Giuseppe Sanguineti ◽  
Antonello Vidiri ◽  
Giovanna Rizzo
Keyword(s):  
Lymph Nodes ◽  
Tumor Response ◽  
Early Prediction ◽  
Cervical Lymph Nodes ◽  
Modal Approach

scholarly journals Psorinum Therapy in Treating Stomach, Gall Bladder, Pancreatic, and Liver Cancers: A Prospective Clinical Study

2011 ◽  
Vol 2011 ◽  
pp. 1-7 ◽  
Author(s):  
Aradeep Chatterjee ◽  
Jaydip Biswas ◽  
Ashim Chatterjee ◽  
Sudin Bhattacharya ◽  
Bishnu Mukhopadhyay ◽  
...  
Keyword(s):  
Gall Bladder ◽  
Cancer Treatment ◽  
Tumor Response ◽  
Final Analysis ◽  
Controlled Clinical Trial ◽  
Prospective Clinical Study ◽  
Eligibility Criteria ◽  
Double Blind ◽  
Scientific Exploration ◽  
Liver Cancers

We prospectively studied the clinical efficacy of an alternative cancer treatment “Psorinum Therapy” in treating stomach, gall bladder, pancreatic and liver cancers. Our study was observational, open level and single arm. The participants' eligibility criteria included histopathology/cytopathology confirmation of malignancy, inoperable tumor, and no prior chemotherapy or radiation therapy. The primary outcome measures of the study were (i) to assess the radiological tumor response (ii) to find out how many participants survived at least 1 year, 2 years, 3 years, 4 years and finally 5 years after the beginning of the study considering each type of cancer. Psorinum-6x was administered orally to all the participants up to 0.02 ml/Kg body weight as a single dose in empty stomach per day for 2 years along with allopathic and homeopathic supportive cares. 158 participants (42 of stomach, 40 of gall bladder, 44 of pancreatic, 32 of liver) were included in the final analysis of the study. Complete tumor response occurred in 28 (17.72%) cases and partial tumor response occurred in 56 (35.44%) cases. Double-blind randomized controlled clinical trial should be conducted for further scientific exploration of this alternative cancer treatment.

scholarly journals 18F-Alfatide II and 18F-FDG Dual-Tracer Dynamic PET for Parametric, Early Prediction of Tumor Response to Therapy

2013 ◽  
Vol 55 (1) ◽  
pp. 154-160 ◽  
Author(s):  
J. Guo ◽  
N. Guo ◽  
L. Lang ◽  
D. O. Kiesewetter ◽  
Q. Xie ◽  
...  
Keyword(s):  
Tumor Response ◽  
Response To Therapy ◽  
Early Prediction ◽  
Dynamic Pet ◽  
18F Fdg ◽  
Dual Tracer

scholarly journals Early Prediction of Tumor Response to Neoadjuvant Chemotherapy and Clinical Outcome in Breast Cancer Using a Novel FDG-PET Parameter for Cancer Stem Cell Metabolism

2020 ◽  
Vol 10 (3) ◽  
pp. 132
Author(s):  
Chanwoo Kim ◽  
Sang-Ah Han ◽  
Kyu Yeoun Won ◽  
Il Ki Hong ◽  
Deog Yoon Kim
Keyword(s):  
Breast Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Fdg Pet ◽  
Triple Negative ◽  
Tumor Response ◽  
Pathologic Complete Response ◽  
Metabolic Parameters ◽  
Metabolic Phenotype ◽  
Early Prediction ◽  
Her2 Positive

Cancer stem cells (CSCs) contribute to chemoresistance and tumor relapse. By using the distinct metabolic phenotype of CSC, we designed novel PET parameters for CSC metabolism and investigated their clinical values. Patients with breast cancer who underwent 18F-FDG PET/CT before neoadjuvant chemotherapy (NAC) were retrospectively included. We developed a method to measure CSC metabolism using standardized uptake value histogram data. The predictive value of novel CSC metabolic parameters for pathologic complete response (pCR) was assessed with multivariable logistic regression. The association between the CSC parameter and disease-free survival (DFS) was also determined. We identified 82 patients with HER2-positive/triple-negative subtypes and 38 patients with luminal tumors. After multivariable analysis, only metabolic tumor volume for CSC (MTVcsc) among metabolic parameters remained the independent predictor of pCR (OR, 0.12; p = 0.022). MTVcsc successfully predicted pathologic tumor response to NAC in HER2-positive/triple-negative subtypes (accuracy, 74%) but not in the luminal subtype (accuracy, 29%). MTVcsc was also predictive of DFS, with a 3-year DFS of 90% in the lower MTVcsc group (<1.75 cm3) versus 72% in the higher group (>1.75 cm3). A novel data-driven PET parameter for CSC metabolism provides early prediction of pCR after NAC and DFS in HER2-positive and triple-negative subtypes.

Sign in / Sign up

Export Citation Format

Share Document